Association Health Plans
Executive Summary
The Blue Cross/Blue Shield Association is lobbying against association health plans as its top legislative priority in 2003. In a story on BCBSA's approach to the generic drug debate this year, "The Pink Sheet" incorrectly stated the association's position on the health plan issue (1"The Pink Sheet" May 19, 2003, p. 30)...
You may also be interested in...
Blue Cross/Blue Shield Testing Generic Drug Ad Themes For 2003
The Blue Cross/Blue Shield Association is developing an ad campaign with the message that expanded use of generic drugs will free up resources to spend on future medical innovations
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.